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A75-year-old-man with previous coronary artery bypass graft surgery and mitral valvereplacement with a 27-mm St. Jude porcine valve was in New York Heart Associa-tion (NYHA) functional class III due to dysfunctional mitral bioprosthesis (A 
2-dimensional echocardiography and Doppler trace of the mitral valve before and after inter-
vention). A percutaneous transvenous mitral valve implantation with a “valve-in-valve” technique
was proposed. To assess feasibility, a 3-dimensional print of the patient’s heart was obtained from a
gated cardiac computed tomography scan. Rapid prototyping confirmed in vitro that the transfemo-
ral delivery system used for transcatheter aortic valve implantation (Sapien XT, Edwards Life-
sciences, Irvine, California) could be used to deliver a stented valve in the mitral position through a
transseptal approach. A 26-mm Sapien XT valve (Edwards Lifesciences) was deployed successfully
within the dysfunctional mitral bioprosthesis through the right femoral vein (B, Online Video 1).
Three-dimensional transesophageal echocardiography demonstrated procedural outcome (C, Online
Videos 2 and 3). The iatrogenic atrial septal defect (ASD) was closed with a 20-mm ASD closure
device (Occulotech, Jena, Germany). The patient was discharged in 48 h. The patient’s functional
class improved to NYHA functional class I at 6-month follow-up.
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